J. Safra Sarasin Holding AG Sells 9,116 Shares of Elevance Health, Inc. $ELV

J. Safra Sarasin Holding AG lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 63.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,285 shares of the company’s stock after selling 9,116 shares during the period. J. Safra Sarasin Holding AG’s holdings in Elevance Health were worth $1,853,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ELV. Nilsine Partners LLC lifted its holdings in Elevance Health by 1.5% during the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after purchasing an additional 29 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its holdings in Elevance Health by 3.0% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after buying an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its position in shares of Elevance Health by 4.4% during the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after buying an additional 31 shares during the period. Detalus Advisors LLC lifted its holdings in shares of Elevance Health by 1.8% in the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after buying an additional 31 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its holdings in shares of Elevance Health by 6.1% in the fourth quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock worth $195,000 after buying an additional 32 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Trading Up 2.9%

Shares of ELV stock opened at $293.10 on Wednesday. The business has a 50-day moving average price of $318.92 and a two-hundred day moving average price of $332.55. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market cap of $64.38 billion, a P/E ratio of 11.67, a price-to-earnings-growth ratio of 1.56 and a beta of 0.51.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 2.3%. The ex-dividend date was Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.39%.

Analyst Ratings Changes

Several equities analysts recently commented on ELV shares. Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research note on Tuesday, February 3rd. Wells Fargo & Company cut their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Weiss Ratings lowered shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 2nd. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Jefferies Financial Group dropped their price objective on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.